# **Expression Pattern of MAGEA3 and MAGEA4 in Lung Cancer** Jina Yom<sup>1</sup>, Rachel Gonzalez<sup>1</sup>, Aubrey Su<sup>1</sup>, Xiaomin Hu<sup>2</sup>, Qi Ren<sup>2</sup>, Zhaoying Guo<sup>1</sup>, Yan Ma<sup>1</sup>, Ranran Zhang<sup>2</sup>, Xuan Liu<sup>1</sup>, Wei Fu<sup>1</sup>



## Abstract

Lung cancer represents 25% of all cancer deaths in the world. Through time, treatments have improved 5-year survival rates for early-stage lung cancer. New treatment targets are needed for advanced stage lung cancers. Melanoma-associated antigen gene A (MAGEA) family proteins expressed in a variety of tumors with each MAGEA protein having unique roles in cancer pathogenesis. One advantage of targeting MAGEA family members is the lack of expression in normal tissues which makes them well suited for targeted cancer immunotherapy for advanced stage cancers. The challenge in screening MAGEA family is to find a specific antibody since the 12-member family has over 60% homology in sequence. In this study, multiple MAGEA3 and MAGEA4 antibodies were evaluated using CytoSections. A specific antibody to each MAGEA3 and MAGEA4 protein was identified, which were used to screen twenty-two non-small cell lung cancer (NSCLC) tissue samples. The screen results showed that MAGEA3 was present in 14 of the 22 lung cancers, while MAGEA4 was present in 10 of the 22 lung cancers evaluated. 3 cancers were strong positives and 4 cancers were weak positives for both targets. Another 4 tumors had positivity for both targets, but the area of positivity did not overlap. These findings show that MAGEA3 was frequently present in the immune cells adjacent to lung cancer while MAGEA4 was only detected 3 times in the immune cells surrounding the tumor.


## Introduction

Recently clinical trials have started targeting melanoma associated antigen 3 and 4 (MAGEA3 and MAGEA4) in lung cancer. If the trials are successful, having good diagnostic antibodies for MAGEA3 or MAGEA4 proteins will be needed for determining patients' therapy with these targets. Establishing specificity is challenging for genes in the same family, when there are significant overlapping sequences. It has been shown that MAGEA family members have 60 to 90% sequence overlap. Here we show how testing the specificity of antibody against this large gene family is doable with CytoSections

Instead of finding unique tissues that express each of the twelve MAGEA family members individually, CytoSections are used to express each target. Unlike cell lines, which often have protein expression change in culture, CytoSections will remain as a uniform control with set expression levels. Production of CytoSections is illustrated in the cartoon of Figure 1.

Eight different MAGEA3 and MAGEA4 antibodies were assessed using CytoSections for specificity to their targets, which resulted in highly specific antibodies for MAGEA3 and MAGEA4, respectively, to screened 22 lung cancers. The results showed MAGEA3 and MAGEA4 can both be present in the lung cancer at the same time. However, many tumors expressed only one protein. Expression of both MAGEA3 and MAGEA4 in the same tumors did not always overlap within the same cells. Greater than 60% of the tumors had MAGEA3 expression in the infiltrating immune cells. This study reveals the complexity of the MAGEA3 and MAGEA4 protein expression in lung cancer.

# **Design & Methods**



### Immunocytochemistry

Manual IHC staining of paraffin-embedded CytoSections and tissues using anti MAGEA3 and 4 antibodies (Table 1). All antibodies required heat induced epitope retrieval HIER using OriGene-Citrate pH6.0 buffer for all MAGEA antibodies. OriGene's Polink-1 a one-step anti- mouse polymer HRP detection (Cat# D12-100) and DAB chromogen was used according to manufacturer's protocol. Tissues were sourced from OriGene Technology's tissue collection. Scoring was based on the percentage of positive cells and not the intensity.

### Table 1 MAGEA-3, 4, & 9 Antibodies

MAGEA3	MAGEA3	MAGEA4	MAGEA4
Ab Clone #	Ab SKU #	Ab Clone #	Ab SKU #
OTI1H1	TA800826	OTI1F9	TA505362
OTI1G9	TA800804	OTI2C1	TA505361
OTIF210	TA800802	OTI5E8	TA505423
OTI1A9	TA800828	OTI1F12	TA505396


### Table 3 MAGEA3 and 4 Antibody Detection Pattern on MAGEA1-12

Antitodoy sku# OTI11C3 OTI1H1 OTI1G9 OTI2F10	OTI1A9 OTI1F9 OTI2C1 OT	OTI5E8 OTI1F12	
AntibodyTarget DDK - MAGE-A3 MAGE-A3 MAGE-A3	MAGE-A3 MAGE-A4 MAGE-A4 MA	MAGE-A4 MAGE-A4	
CytoSection Dilution = 1:600 Dilution = 1:10000 Dilution = 1:2000 Dilution = 1:2	0 Dilution = 1:2000 Dilution = 1:1000 Dilution = 1:10000 Dilu	Dilution = 1:1000 Dilution = 1:1000	
MAGE-A1 95 0 0	5 0 95 0	95 0	
MAGE-A2 95 5 0	5 5 0 0	0 0	
MAGE-A3 100 10 100	<b>5 95</b> 0 0	95 95	
MAGE-A4 v1 100 0 0	5 0 <b>95 0.1</b>	95 95	
MAGE-A4 v2 10 0 0	5 0 <b>10 10</b>	10 10	
MAGE-A4 v3 10 0.01 0	a 0 <b>10 10</b>	10 10	Table 2 MAGEA Family Member 1-12 CytoSections Images Map
MAGE-A4 v4 10 0 0	0 0 10 10	10 10	Table 2 MAOLAT anny Member 1-12 Cytobections images map
MAGE-A5 10 0 0	5 0 0 0	90 10	MAGEA1-12 CytoSection Map
MAGE-A6 100 10 10 10	5 <mark>10</mark> 00	95 10	
MAGE-A8 10 0 0	0 0 10 0	10 10	MAGE-A1 TS402134 MAGE-A2 TS423561 MAGE-A3 TS403288 MAGE-A4v1 TS418952 MAGE-4v2 TS423938
MAGE-A9 10 0 0.1	0 0 5 0	0 0	
MAGE-A10 10 0 0	0 0 5 0	0 0	MAGE-A4v3 TS404482 MAGE-4v4 TS423561 MAGE-A5 TS418575 MAGE-A6 TS423578 MAGE-A8 TS429878
MAGE-A11 10 0.01 0	1 0 0 0	5 5	
MAGE-A12 10 0 10	3 0 0.1 0	5 5	MAGE-A9 TS401760 MAGE-A10 TS402501 MAGE-A11 TS402471 MAGE-A12 TS429868 HEK293T CONTROL
NEG CONTROL 0 0 0		0 0	

1) OriGene Technologies Inc.; 9620 Medical Center Drive, Suite 201, Rockville MD 20850 2) OriGene Wuxi Biotechnology Co., Ltd. No.168, Meiliang Road, Binhu District Wuxi, Jiangsu



Fig 2 DDK, MAGEA3, and MAGEA4 antibodies on MAGEA1-12 CytoSections	Fig 3 M/	AGEA3 ar
As anti-DDK clone OTI1C3 SKU# TA180144		GEA3 G CAI
Ms anti-MAGEA3 clone OTI1H1 SKU# TA800826		
	Table 4	Western /
	TISSUE	TUMOR MAGEA3
A CALL AND A	1	POS
		POS
Ms anti-MAGEA4 clone OTI2C1 SKU# TA505361	3	NEG
	4	POS
	5	POS
	6	NEG
	7	NEG
	8	POS
	9	POS
	10	NEG
	11	POS
	12	NEG
	13	NEG
	14	POS
	15	POS
Table 2         MAGEA Family Member 1-12         CytoSections Images Map		POS
MAGEA1-12 CytoSection Map	17	POS



## Anti DDK 1:3000 on 10ug of MAGEA1-12 Lysate


			IMMUNE	IMMUNE	
TISSUE	TUMOR	TUMOR	CELLS	CELLS	Tumor Overlap
	MAGEA3	MAGEA4	MAGEA3	MAGEA4	MAGEA3w4
1	POS	NEG	NEG	NEG	DIFFERENT
2	POS	POS	NEG	NEG	YES
3	NEG	POS	NEG	POS	DIFFERENT
4	POS	POS	POS	NEG	YES
5	POS	POS	POS	NEG	DIFFERENT
6	NEG	NEG	POS	NEG	YES
7	NEG	NEG	NEG	POS	DIFFERENT
8	POS	NEG	NEG	NEG	DIFFERENT
9	POS	POS	POS	NEG	DIFFERENT
10	NEG	NEG	POS	NEG	DIFFERENT
11	POS	POS	POS	NEG	YES
12	NEG	NEG	NEG	NEG	DIFFERENT
13	NEG	NEG	POS	NEG	DIFFERENT
14	POS	NEG	POS	NEG	DIFFERENT
15	POS	NEG	POS	NEG	DIFFERENT
16	POS	NEG	POS	NEG	DIFFERENT
17	POS	POS	POS	POS	YES
18	NEG	NEG	NEG	NEG	DIFFERENT
19	NEG	POS	NEG	NEG	DIFFERENT
20	POS	POS	POS	NEG	YES
21	POS	POS	POS	NEG	YES
22	POS	NEG	POS	NEG	DIFFERENT

## Results

### and MAGEA4 antibodies on Lung Cancer Tissues

### Ms anti-MAGEA3 clone OTI1H1 SKU# TA80082

Fig 4 Examples of Positive and Negative staining in Lung Cancer Tissue for MAGEA3 and MAGEA4



## Conclusion

- Specific antibodies were identified for both MAGEA3 and MAGEA4 for screening in tissue
- MAGEA3 and MAGEA4 can be co-expressed in lung cancer, but it is not always expressed in the same cell
- MAGEA3 is frequently expressed in infiltrating immune cells even when the tumor is negative for MAGEA3
- MAGEA4 is rarely expressed in infiltrating immune cells
- CytoSections can reduce the time required to find the right tissue and mitigate the use of rare and less stable FFPE tissues

## **Booth 117**

